AR044490A1 - Formulaciones para tratamientos de base opioidea para el dolor que comprenden derivados sustituidos de 1,4 - di- piperidin - 4- il- piperazina - Google Patents
Formulaciones para tratamientos de base opioidea para el dolor que comprenden derivados sustituidos de 1,4 - di- piperidin - 4- il- piperazinaInfo
- Publication number
- AR044490A1 AR044490A1 ARP040101992A ARP040101992A AR044490A1 AR 044490 A1 AR044490 A1 AR 044490A1 AR P040101992 A ARP040101992 A AR P040101992A AR P040101992 A ARP040101992 A AR P040101992A AR 044490 A1 AR044490 A1 AR 044490A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- halo
- radical
- amino
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 8
- 208000002193 Pain Diseases 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 3
- -1 cyano, hydroxy, formyl Chemical group 0.000 abstract 16
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 239000000014 opioid analgesic Substances 0.000 abstract 3
- 229940005483 opioid analgesics Drugs 0.000 abstract 3
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000001544 thienyl group Chemical group 0.000 abstract 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 2
- 206010038678 Respiratory depression Diseases 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 abstract 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 125000002541 furyl group Chemical group 0.000 abstract 2
- 229930195733 hydrocarbon Natural products 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000002632 imidazolidinyl group Chemical group 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- 125000001041 indolyl group Chemical group 0.000 abstract 2
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 2
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000002971 oxazolyl group Chemical group 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 2
- 230000020341 sensory perception of pain Effects 0.000 abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 abstract 2
- TYYZPUUMIWNDKS-UHFFFAOYSA-N 1,4-di(piperidin-4-yl)piperazine Chemical class C1CNCCC1N1CCN(C2CCNCC2)CC1 TYYZPUUMIWNDKS-UHFFFAOYSA-N 0.000 abstract 1
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005883 dithianyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000002636 imidazolinyl group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 125000001422 pyrrolinyl group Chemical group 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
- 125000004306 triazinyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Formulaciones para tratamientos de base opioidea, para el dolor y/o nocicepción, que comprenden analgésicos opioideos y derivados sustituidos de 1,4-di-piperidin-4-il-piperazina que tienen actividad antagonista de neuroquinina, en particular actividad antagonista del receptor de NK1, uso de dicha formulación para la manufactura de un medicamento para la prevención y/o tratamiento de la emesis, dolor y/o nocicepción, en particular en los tratamientos de base opioidea para el dolor crónico y agudo, más particularmente para los tratamientos del dolor inflamatorio, post-operatorio, de servicio de urgencias (ER), intercurrente, neuropático y de cáncer, y uso de un antagonista del receptor de NK1 para la manufactura de un medicamento, para la prevención y/o tratamiento de la depresión respiratoria y tolerancia en los tratamientos de base opioidea para el dolor. La composición farmacéutica reduce en gran medida una variedad de efectos secundarios indeseables que están asociados con los analgésicos opioideos, en particular emesis, depresión respiratoria y tolerancia, aumentando de esta manera la tolerabilidad total de dichos opioideos en el tratamiento del dolor. Reivindicación 1: Una composición farmacéutica que comprende un portador farmacéuticamente aceptable, y como ingredientes activos, un analgésico opioide y una cantidad terapéuticamente eficaz de un compuesto de acuerdo con la fórmula (1), las sales de adición de ácido o bases farmacéuticamente aceptables del mismo, las formas estereoquímicamente isoméricas del mismo, la forma N-óxido del mismo y los profármacos del mismo, donde: n es un número entero, igual a 0, 1 ó 2; m es un número entero, igual a 1 ó 2, con la condición de que si m es 2, entonces n sea 1; p es un número entero, igual a 1 ó 2; Q es O ó NR3; X es un enlace covalente o un radical divalente de fórmula -O-, -S- o -NR3-; cada R3 independientemente uno del otro es H o alquilo; cada R1 independientemente uno del otro se selecciona del grupo de Ar1, Ar1-alquilo y di(Ar1)-alquilo; q es un número entero igual a 0 o 1; R2 es alquilo, Ar2, Ar2-alquilo, Het1 o Het1-alquilo; Y es un enlace covalente o un radical divalente de fórmula -C(=O)- o -SO2-; cada Alk representa, independientemente uno del otro, un enlace covalente; un radical hidrocarbonado divalente, de cadena recta o ramificada, saturado o no saturado, que tiene de 1 a 6 átomos de C, o un radical hidrocarbonado cíclico saturado o no saturado que tiene de 3 a 6 átomos de C; y cada radical está opcionalmente sustituido en uno o más átomos de C con uno o más radicales alquilo, fenilo, halo, ciano, hidroxi, formilo, y amino; L se selecciona del grupo de H, alquiloxi, Ar3-oxi, alquilcarbonilo, mono- y di(alquil)amino, mono- y di(Ar3)amino, Ar3, Ar3-carbonilo, Het2 y Het2-carbonilo; Ar1 es fenilo, opcionalmente sustituido con 1, 2 o 3 sustituyentes, cada uno independientemente uno del otro seleccionado del grupo de halo, alquilo, ciano, aminocarbonilo y alquiloxi; Ar2 es naftalenilo o fenilo, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes, cada uno independientemente uno del otro seleccionado del grupo de halo, nitro, amino, mono- y di(alquil)amino, ciano, alquilo, hidroxi, alquiloxi, carboxilo, alquilcarbonilo, aminocarbonilo y mono- y di(alquil)aminocarbonilo; Ar3 es naftalenilo o fenilo, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes, cada uno independientemente uno del otro seleccionado del grupo de alquiloxi, alquilo, halo, hidroxi, piridinilo, morfolinilo, pirrolidinilo, imidazo[1,2-a]piridinilo, morfolinilcarbonilo, pirrolidinilcarbonilo, amino y ciano; Het1 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolilo, pirazolilo, imidazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo y piridazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de quinolinilo, quinoxalinilo, indolilo, benzimidazolilo, benzxazolilo, benzisoxazolilo, benztiazolilo, benzisotiazolilo, benzofuranilo y benzotienilo; cada radical heterocíclico monocíclico y bicíclico puede estar sustituido opcionalmente en cualquier átomo con un radical seleccionado del grupo de halo y alquilo; Het2 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolidinilo, dioxolilo, imidazolidinilo, pirrazolidinilo, piperidinilo, morfolinilo, ditianilo, tiomorfolinilo, piperazinilo, imidazolidinilo, tetrahidrofuranilo, 2H-pirrolilo, pirrolinilo, imidazolinilo, pirrazolinilo, pirrolilo, imidazolilo, pirazolilo, triazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, tiadiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo y triazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de benzopiperidinilo, quinolinilo, quinoxalinilo, indolilo, isoindolilo, cromenilo, benzimidazolilo, imidazo[1,2-a]piridinilo, benzoxazolilo, benzisoxazolilo, benzotiazolilo, benzisotiazolilo, benzofuranilo y benzotienilo, cada radical monocíclico y bicíclico opcionalmente sustituido con uno o más radicales seleccionados del grupo de Ar1, Ar1alquilo, halo, hidroxi, alquilo, piperidinilo, pirrolilo, tienilo, oxo, alquiloxi, alquiloxialquilo y alquiloxicarbonilo; y alquilo es un radical hidrocarbonado saturado de cadena recta o ramificada que tiene de 1 a 6 átomos de C, o un radical hidrocarbonado cíclico saturado que tiene de 3 a 6 átomos de C; opcionalmente sustituido en uno o más átomos de C con uno o más radicales seleccionados del grupo de radicales fenilo, halo, ciano, oxo, hidroxi, formilo y amino.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP0350220 | 2003-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044490A1 true AR044490A1 (es) | 2005-09-14 |
Family
ID=33547567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101992A AR044490A1 (es) | 2003-06-10 | 2004-06-09 | Formulaciones para tratamientos de base opioidea para el dolor que comprenden derivados sustituidos de 1,4 - di- piperidin - 4- il- piperazina |
Country Status (16)
Country | Link |
---|---|
US (1) | US20060128721A1 (es) |
EP (1) | EP1635811A2 (es) |
JP (1) | JP2006527236A (es) |
KR (1) | KR20060006098A (es) |
CN (1) | CN1822828A (es) |
AR (1) | AR044490A1 (es) |
AU (1) | AU2004246817A1 (es) |
BR (1) | BRPI0411290A (es) |
CA (1) | CA2527856A1 (es) |
CL (1) | CL2004001421A1 (es) |
IL (1) | IL172423A0 (es) |
MX (1) | MXPA05013295A (es) |
MY (1) | MY144580A (es) |
TW (1) | TW200510382A (es) |
WO (1) | WO2004110415A2 (es) |
ZA (1) | ZA200510044B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2485B1 (en) * | 2002-12-23 | 2009-01-20 | شركة جانسين فارماسوتيكا ان. في | 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists |
FR2879460B1 (fr) * | 2004-12-17 | 2007-02-23 | Sod Conseils Rech Applic | Associations anti-douleur comprenant un derive de dihydroimidazopyrazine |
US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
WO2006071958A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
MX2007010728A (es) * | 2005-03-03 | 2007-10-12 | Janssen Pharmaceutica Nv | Derivados sustituidos de oxa-diaza-espiro-[5.5]-undecanona y su uso como antagonistas de la neurocinina. |
NZ556628A (en) | 2005-03-08 | 2009-09-25 | Janssen Pharmaceutica Nv | Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists |
EP2021005A4 (en) * | 2006-05-03 | 2009-11-25 | Cnsbio Pty Ltd | METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN |
US7842662B2 (en) | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
CA3120681A1 (en) * | 2012-04-17 | 2013-10-24 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
EP2954037B1 (en) | 2013-02-08 | 2018-04-11 | General Mills, Inc. | Reduced sodium food products |
US9505718B2 (en) * | 2013-03-15 | 2016-11-29 | Nanyang Technological University | 3-piperidone compounds and their use as neurokinin-1 (NK1) receptor antagonists |
RU2617409C1 (ru) * | 2015-12-24 | 2017-04-25 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | Амиды акриловой и метакриловой кислот с n-алкилпиперазино-пиперидинами и способ их получения |
CN108503579B (zh) * | 2018-03-28 | 2021-03-26 | 南京医科大学 | 芬太尼类似物及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2287404A (en) * | 1994-03-15 | 1995-09-20 | Pfizer | Antiinflammatory and analgesic compositions |
GB9426102D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
AU2243897A (en) | 1996-01-17 | 1997-08-11 | Eli Lilly And Company | Methods of treating or preventing pain or nociception |
AU7788500A (en) | 1999-10-25 | 2001-05-08 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
US6642226B2 (en) | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
MY141736A (en) * | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
-
2004
- 2004-06-07 CA CA002527856A patent/CA2527856A1/en not_active Abandoned
- 2004-06-07 US US10/560,476 patent/US20060128721A1/en not_active Abandoned
- 2004-06-07 KR KR1020057023011A patent/KR20060006098A/ko not_active Application Discontinuation
- 2004-06-07 JP JP2006516137A patent/JP2006527236A/ja not_active Withdrawn
- 2004-06-07 AU AU2004246817A patent/AU2004246817A1/en not_active Abandoned
- 2004-06-07 MX MXPA05013295A patent/MXPA05013295A/es unknown
- 2004-06-07 CN CNA2004800202370A patent/CN1822828A/zh active Pending
- 2004-06-07 EP EP04766038A patent/EP1635811A2/en not_active Withdrawn
- 2004-06-07 BR BRPI0411290-3A patent/BRPI0411290A/pt not_active IP Right Cessation
- 2004-06-07 WO PCT/EP2004/051048 patent/WO2004110415A2/en active Application Filing
- 2004-06-08 MY MYPI20042196A patent/MY144580A/en unknown
- 2004-06-08 CL CL200401421A patent/CL2004001421A1/es unknown
- 2004-06-09 TW TW093116490A patent/TW200510382A/zh unknown
- 2004-06-09 AR ARP040101992A patent/AR044490A1/es not_active Application Discontinuation
-
2005
- 2005-12-07 IL IL172423A patent/IL172423A0/en unknown
- 2005-12-09 ZA ZA200510044A patent/ZA200510044B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2527856A1 (en) | 2004-12-23 |
EP1635811A2 (en) | 2006-03-22 |
BRPI0411290A (pt) | 2006-08-29 |
IL172423A0 (en) | 2006-04-10 |
CL2004001421A1 (es) | 2005-05-27 |
ZA200510044B (en) | 2007-04-25 |
TW200510382A (en) | 2005-03-16 |
WO2004110415A3 (en) | 2005-02-10 |
JP2006527236A (ja) | 2006-11-30 |
WO2004110415A2 (en) | 2004-12-23 |
MXPA05013295A (es) | 2006-03-09 |
KR20060006098A (ko) | 2006-01-18 |
CN1822828A (zh) | 2006-08-23 |
US20060128721A1 (en) | 2006-06-15 |
MY144580A (en) | 2011-10-14 |
AU2004246817A1 (en) | 2004-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR044490A1 (es) | Formulaciones para tratamientos de base opioidea para el dolor que comprenden derivados sustituidos de 1,4 - di- piperidin - 4- il- piperazina | |
AR041545A1 (es) | Derivados sustituidos de 1,4-di-piperidin-4 il-piperazina y su uso como antagonistas de neuroquininas | |
TW492882B (en) | Cholinergic antagonist plaster composition | |
AR040673A1 (es) | Inhibidores micobacterianos, composicion farmaceutica y proceso de preparacion del compuesto | |
RS20050522A (en) | Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation | |
BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
TR200102005T2 (tr) | Poli(adp-ribaz) polimerazların trisiklik inhibitörleri. | |
TW200624427A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
AR034270A1 (es) | 1-aril- o 1-alquilsulfonil-heterociclilbenzazoles como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
TW200626572A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
TW200626592A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
AR027548A1 (es) | Derivados de amino pirazol utiles para el tratamiento de la obesidad y otros desordenes | |
TW200626558A (en) | Indazolone derivatives | |
TW200626153A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
TW200626148A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
TW200626139A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
ECSP066314A (es) | Derivados piridilo y su uso como agentes terapéuticos | |
NO20062004L (no) | Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav | |
AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
AR045913A1 (es) | Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina | |
AR042651A1 (es) | Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininas | |
TR200103613T2 (tr) | Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler. | |
BR112018067906A2 (pt) | métodos de tratamento de depressão usando antagonistas do receptor de orexina-2 | |
CA2509406A1 (en) | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |